WinSanTorâs mission is simple-develop a drug that works. We recognize that there are no treatments for this disease today. Thus, WinSanTor is striving to impact the lives of todayâs patients heavily burdened by peripheral neuropathy. We are impatient. We are exploiting every strategy, mechanism, and regulation to accelerate approval of our drugs, including recycling a previously approved safe drug. Phase 1 is complete and we are now starting phase 2. Our goal is to get drug approval in the US by 2021 and perhaps sooner elsewhere. By focusing on patient impact rather than the bottom line, we believe weâre creating a new sustainable model for pharma companies based on patient need, not just money. Source
No articles found.
CannaKorp, Inc. is a technology start-up company that is simplifying and improving...
CannaKorp, Inc. is a technology start-up compan...
Eliot's produces peanut and nut butters featuring US grown nuts based in Portland ...
Eliot's produces peanut and nut butters featuri...
BioLife Solutions is the leading developer, manufacturer and supplier of proprieta...
BioLife Solutions is the leading developer, man...
UNITY Biotechnology is developing therapeutics to extend human healthspan by slowi...
UNITY Biotechnology is developing therapeutics ...
Arcturus Therapeutics is developing portfolio of RNA therapeutics for treatment of...
Arcturus Therapeutics is developing portfolio o...
Trevena is a biopharmaceutical company focused on the development and commercializ...
Trevena is a biopharmaceutical company focused ...
Osmotica Pharmaceuticals plc is a fully-integrated biopharmaceutical company focus...
Osmotica Pharmaceuticals plc is a fully-integra...
Join the National Investor Network and get the latest information with your interests in mind.